IHF to support OmiX iAMP for combined testing of COVID-19

6 122
Madhav Joshi, CEO, IHF

DTMT Network

India Health Fund (IHF) seeded by Tata Trusts, with strategic assistance from the Global Fund to fight AIDS, Tuberculosis and Malaria, has announced its support on September 14, 2021 for OmiX Laboratories for its OmiX iAMP platform.

The OmiX iAMP platform is a Multiplex Loop-mediated Isothermal Amplification (LAMP) innovation-based solution that does combine testing of COVID-19, TB, and influenza.

IHF in a statement has said that it will support OmiX Laboratories towards manufacturing of devices, clinical validation and enable linkages, and support for regulatory approval, certifications, and CE submission.

“The application of the latest developments in science and technology to develop solutions which can help improve outcomes in the diagnosis, treatment & prevention of communicable diseases has lagged behind developments in non-communicable diseases,” CEO of IHF, Madhav Joshi, said.

“The COVID-19 pandemic has highlighted this gap, and the health system had to make tools which were inadequate to meet the need for accurate and low-cost solutions which could be used at scale without putting an additional burden on healthcare workers,” he added.

“Since inception four years ago, India Health Fund has focused on helping bridge this gap by de-risking the development of promising technology-led solutions and enabling their growth,” Joshi explained.

“We believe OMIX iAMP can be a game-changer by enabling low cost, accurate, differentiated diagnosis of COVID19, TB and Influenza at scale which will significantly improve patient outcomes and public health with early & accurate diagnosis, initiation of the right treatment and reducing the risk of undetected infection spreading,” he further said.

Dr. Sudeshna Adak, Co-founder of OmiX Laboratories Pvt. Ltd., said, “Poor healthcare outcomes are directly correlated with socioeconomic status, and it begins with lack of access to accurate and early diagnosis. Imagine being sick and the nearest laboratory is 50 km away or the cost of a test is equal to a week’s wages.”

“The COVID-19 pandemic was yet another reminder where access to RT-PCR diagnostic laboratories in smaller towns and cities in India lagged well behind the metros. OmiX’s journey is to revolutionise diagnostics to enable access to accurate and affordable molecular diagnostics not just for COVID-19, but also other debilitating infections such as Tuberculosis and Influenza,” Dr. Adak said.



  1. Be first to post your comments

Your Comment

Your email address will not be published. Required fields are marked *



Back to Top